Chalwe Diallo, MBA
About Chalwe Diallo, MBA
Chalwe Diallo, MBA, is a Sr. CMC Project Manager at Bristol Myers Squibb, with extensive experience in project management, portfolio strategy, and integration within the biotech industry.
Company
Chalwe Diallo currently holds the role of Sr. CMC Project Manager, Portfolio Strategy & Integration at Bristol Myers Squibb. This position involves managing complex projects, optimizing processes, and advancing technology in the biotech industry. He is responsible for driving projects and developing high-level strategies for clinical drug development programs.
Title
Chalwe Diallo serves as Sr. CMC Project Manager, Portfolio Strategy & Integration. In this capacity, he proactively finds solutions to narrow down risks in complex problems and has significant experience in portfolio strategy and integration within the biotech sector.
Education and Expertise
Chalwe Diallo earned a Master's degree in Business Administration and Management from Penn State University between 2015 and 2017. He also holds a Bachelor of Science in Chemistry from Lincoln University, completed between 2009 and 2013. Diallo’s education is complemented by additional studies at Mahidol University International College in Chemistry, International College of Seville in Spanish, and the Semester at Sea program.
Professional Background
Before his current role at Bristol Myers Squibb, Chalwe Diallo accumulated extensive experience at Regeneron, where he held several positions such as Project Associate - CMC Program Management, Black Employee Resource Group Leadership Team member, Sr. Project Coordinator - CMC Program Management, and Associate University Relations Specialist. He also worked at Korn Ferry in 2019 as an Associate Recruiter and at Select Medical from 2017 to 2018 as an Onboarding Specialist.
Achievements
Chalwe Diallo has contributed significantly to the biotech and pharmaceutical sectors. At Regeneron, he was part of the Black Employee Resource Group Leadership Team, where he advanced diversity and inclusion initiatives. His sophisticated background in managing projects and developing high-level strategies has been key in driving clinical drug development programs and optimizing processes.